All randomized controlled trials (RCT) that evaluated the use of SGLT-2 inhibitors for patients with NAFLD, regardless of diabetes mellitus status, were included. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.